Claris Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Claris Bio - overview
Established
2020
Location
Jersey City, NJ, US
Primary Industry
Biotechnology
About
Founded in 2020 and based in New Jersey, US, Claris Biotherapeutics, Inc. operates as a biotechnology company that is focused on corneal disease therapies. The company was co-founded by Dr. Reza Dana, MD, MSc, MPH Dr.
Sunil Chauhan, DVM, PhD, and Clarke Atwell (CEO). In January 2024, the firm raised USD 57 million in Series A funding from investors Novo Holdings A/S, RA Capital Management, and Mass General Brigham Ventures, with participation from returning investor Janus Henderson Investors. The company offers a wide range of treatment solutions to treat corneal ulcers, dry eye disease, corneal edema, microbial keratitis, thermal burn, neurotrophic keratitis, and many others. For the treatment of NK, Claris has created a human recombinant dHGF called CSB-001, which is used topically as a 0.
1% ophthalmic solution. The company plans to use the January 2024 funding to support its development and expansion.
Current Investors
Mass General Brigham Ventures, Novo Holdings, RA Capital Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.clarisbio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.